Homer Lane to Retire from Benaroya Research Institute at Virginia Mason
Homer W. Lane Jr., executive director and chief financial officer of Benaroya Research Institute at Virginia Mason (BRI) and vice president of research at Virginia Mason Medical Center, has announced his plans to retire March 1.
“In his seven years with BRI, Lane built a high-performing administrative team and stewarded an increase of 65% in BRI’s annual revenues to more than $70 million,” said Jane Buckner, MD, president of BRI. “Homer’s commitment to our mission, his integrity and business acumen have been great assets toward the success of our organization.”
“Among his many achievements, Homer led the development of BRI’s five-year strategic and financial plan and enhanced the institute’s focus and commitment to research technology,” Buckner said.
Lane previously served as chief financial officer for the Marine Biological Laboratory, a research and educational institution in Massachusetts, after more than two decades in the banking industry. He holds an MBA and a BS in civil engineering from Columbia University.
BRI chief administrative officer Margaret McCormick, PhD, will be promoted to executive director/chief operating officer and Virginia Mason Medical Center vice president of Research, also effective March 1.
About Benaroya Research Institute at Virginia Mason
Benaroya Research Institute at Virginia Mason (BRI) is a world-renowned, non-profit research institute committed to advancing the science that will predict, prevent, reverse and cure diseases of the immune system. BRI researchers uniquely study the immune system in both health and disease, with the ultimate goal of achieving a healthy immune system for each individual. Diseases we study include type 1 diabetes, rheumatoid arthritis, lupus, multiple sclerosis, Crohn’s and colitis as well as allergies and cancer. BRI accelerates discovery through laboratory breakthroughs in immunology that can be translated to clinical therapies. A leader of collaborative initiatives such as the Immune Tolerance Network and Type 1 Diabetes TrialNet, BRI frequently partners with global research institutes, pharmaceutical and biotech companies.
Director, Marketing Communications & External Relations
email@example.com / 206-342-6903